To date, the strategy of using adjunctive TNF-α antagonists instead of corticosteroids to prevent CNS-TB-associated PR/IRIS and improve outcomes has only been explored with thalidomide in children with stage 2 and 3 TB meningitis. Here, TNF is linked to meningitis.